|
||||||||||||||||
| HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
| RNA in DRUG DEVELOPMENT - RNA as a Tool and Target | ||||||||||||||||
| June 24, 2002 | ||||||||||||||||
|
The Knowledge Foundation, Inc., San Diego, CA Nov 6 - 8, 2002 Detailed Agenda available at website!! November 6: Pre - Conference Workshop: Challenges and Opportunities on Commercialzing RNA in Drug Development - From Bench to Business: Bottlenecks in Starting a Biotechnology Company - Clinical Research: Challenges and Requirements - Successfully Launching a Company in the RNA Field - Emerging Investment Opportunities in RNA Technologies November 7 - 8: Main Conference Session Topics are: RNA interference Aptamers Ribozymes RNA as a TOOL for Drug Development RNA Delivery RNA as a Target With exciting developments in RNA therapeutics research emerging every day, it is vital to examine the interaction of RNA with other small molecules. To rationally design new classes of RNA based drugs it is critical to learn about different mechanisms to alter gene expression as well as how RNA can be used either as a target or a tool to achieve this goal. This 2nd international conference will address these key issues along with strategies for RNA based drugs to successfully integrate into the marketplace. Join the international group of experts on RNA to discuss the latest on: - Aptamers - Spiegelmers - Allosterically regulated RNA lassos - siRNA - Novel ribozymes - Ribonomic clusters - Group II introns to develop a gene targeting vector - Silencing gene expression by RNAi - Evolved nucleic acid sensors - Peptide mediated RNA delivery Take advantage of this unique opportunity to hear the state-of-the-art on RNA - therapeutics from leaders in industry and academia. Register today - space is limited |
||||||||||||||||
| Organized by: | The Knowledge Foundation, Inc. | |||||||||||||||
| Invited Speakers: | David Beach, Genetica, Inc. Petra Burgstaller, NascaCell GmbH, Germany David Engelke, University of Michigan Tony Giordano, Nucleonics, Inc. Larry Gold, SomaLogic, Inc. Claudia Hirawat, PTC Therapeutics, Inc. Sumedha Jayasena, Amgen, Inc. Sergej Kazakov, Somagenics, Inc. Ray Kendzior, Toucan Capital Corp. Markus Kurz, Archemix Corp. Alan Lambowitz, University of Texas Stefan Limmer, Ribopharma AG John Marino, CARB Deepa Pakianathan, Dephi Ventures William Phelps, Ribonomics, Inc. Martin Read, University Oxford, UK Bruce Sullenger, Duke University Medical Center Diethild Tornus, Noxxon Pharma AG, Germany Nassim Usman, Ribozyme Pharmaceuticals, Inc. Patrick Weiss, Xeragon Inc. Ellen Welch, PTC Therapeutics, Inc. Brian Wimberly, Rib-X Pharmaceuticals, Inc. Guido Zaman, N.V. Organon, The Netherlands Shawn Zinnen, Ribozyme Pharmaceuticals, Inc. |
|||||||||||||||
| Deadline for Abstracts: | none | |||||||||||||||
| Registration: | you can register either via phone (617-232 7400) or via fax (617-232 9171) or using the secure online registration form at www.knowledgefoundation.com | |||||||||||||||
| E-mail: | meder@knowledgefoundation.com | |||||||||||||||
| Posted by: | Margit Eder | |||||||||||||||
| Host: | ppp-64-115-22-46.broadviewnet.net | |||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||